FreeTheAI

Incyte to Present New Cancer Pipeline Data at ESMO Congress 2026

NeutralMedium impact
INCY$113.07 −0.18%

Incyte Corporation (NASDAQ:INCY) announced that it will present new clinical data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2026. The medical conference takes place October 23 to October 27 in Madrid, where the company will share findings across several difficult-to-treat cancer types.

The presentations highlight early-stage and combination data for key drug candidates, including KRAS G12D inhibitor INCB161734 and bispecific antibody INCA33890. Clinical results will focus on gastrointestinal cancers such as colorectal and pancreatic cancers, as well as ovarian cancer. Incyte noted that these findings help inform its ongoing Phase 3 trials in KRAS G12D and TGFβR2xPD-1 development programs.

Investors will have an opportunity to review the updates during an investor event and webcast hosted by Incyte on October 26, 2026, at 2:30 p.m. ET. Shares of Incyte were trading at $113.10, down 0.18% for the session.

Key points

  • Incyte will present new oncology portfolio data at ESMO Congress 2026 in Madrid from October 23 to 27, 2026.
  • Presentations cover key candidates including INCB161734, INCA33890, and INCB123667 targeting colorectal, pancreatic, and ovarian cancers.
  • The clinical findings inform active Phase 3 development programs in KRAS G12D and TGFβR2xPD-1 studies.
  • Incyte will hold an investor event and webcast on October 26, 2026, to discuss data and updates.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

When is Incyte presenting data at ESMO Congress 2026?

Incyte will present clinical data at ESMO Congress 2026 from October 23 to October 27, 2026, in Madrid.

What drug candidates is Incyte featuring at ESMO 2026?

Incyte is presenting data on INCB161734, INCA33890, and INCB123667 across colorectal, pancreatic, and ovarian cancers.

When is Incyte holding its ESMO investor event?

Incyte will host an investor event and webcast on October 26, 2026, from 2:30 p.m. to 4:00 p.m. ET.